Look at it the other way. The fact that they have’t filed or even provided guidance 5+ years since data lock in the largest oncology immunotherapy market (over 50% of the world, and 15 to 20X the size of tiny UK) only means that they don’t expect FDA to approve under the current circumstances.
When a company is running on fumes, diluting hundreds of millions of shares for years in pennies, talk about starting new trials in the US, but not even provide guidance on FDA BLA submission tells you everything you need to know.
You can continue to live in denial. LP’s financiers and shorts love that!
The game is pretty much over for NWBO unless you consider the endless dilution in pennies as victory! The more time they lose, no one trusts them to execute anything meaningful in the coming years. No serious company takes 5 years since data lock to only apply to one tiny jurisdiction (less than 2-3% of the world’s market in this space) and that too without reimbursement evidence submission and no clarity on FDA. The market cap valuation will continue to plunge as they lose more time and dilute more shares.
Market Data 
Markets 
AI
